Cabaletta Bio Inc. (CABA)

Business: Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases.

IPO Date: 25-Oct-2019

Co-Founder, Chairman, CEO & Pres: Dr. Steven A. Nichtberger M.D.

Pres of Science & Technology: Dr. Gwendolyn K. Binder Ph.D.

Listing: NASDAQ: CABA

Country: United States

Headquarters: Philadelphia, PA

Website: https://www.cabalettabio.com

Market cap: $30.28 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-49.53 Mln

Cash: $109.21 Mln

Total Debt: $0.00 Mln

Insider's Holding: 4.31%

Liquidity: Low

52 Week range: $0.90 - 14.95

Shares outstanding: 28,977,100

5 Years Aggregate:

• CFO: $-86.25 Mln
• EBITDA: $-104.56 Mln
• Net Profit: $-109.02 Mln